How and where to order Xeloda (Capecitabine) 500 mg pills online:

Shop:	PHARM X SELLER - 10% discount coupon 918cc60b466a42ba
Sellers:	CAPECITABINE STORES
Prices:	from $3.08 per pill
Forms:	Capecitabine (Xeloda) 500 mg tablets
Quantity:	10-100 pills
Type:	Capecitabine brand, Xeloda brand and generics
Payment:	Visa, Mastercard, AmEx, Bitcoin
Delivery:	Regular airmail and express courier
Shipping:	Worldwide, including USA, UK, Europe, Canada, Australia



Indications and usage:

Xeloda (Capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for:


• Adjuvant colon cancer: patients with Dukes' C colon cancer.
• Metastatic colorectal cancer: first-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred.
• Metastatic breast cancer:
  - in combination with docetaxel after failure of prior anthracycline-containing therapy
  - as monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen.
• Gastric cancer.
• Pancreatic cancer.
• Esophageal cancer (oesophageal cancer): off-label in the USA.
  
  
  Dosage and administration:
  
  
• Take Xeloda with water within 30 min after a meal.
• Monotherapy: 1250 mg/m2 twice daily orally for 2 weeks followed by a one week rest period in 3-week cycles.
• Adjuvant treatment is recommended for a total of 6 months (8 cycles).
• In combination with docetaxel, the recommended dose of Capecitabine (Xeloda) is 1250 mg/m2 twice daily for 2 weeks followed by a 7-day rest period, combined with docetaxel at 75 mg/m2 as a 1-hour IV infusion every 3 weeks.
• Xeloda dosage may need to be individualized to optimize patient management.
• Reduce the dose of this medication by 25% in patients with moderate renal impairment.
  
  
  Dosage forms and strengths:
  
  Xeloda (Capecitabine) tablets 150 mg and 500 mg.
  
  
  Overdosage:
  
  The manifestations of acute overdose by capecitabine pills would include nausea, vomiting, diarrhea, gastrointestinal irritation and bleeding, and bone marrow depression. Medical management of overdose should include customary supportive medical interventions aimed at correcting the presenting clinical manifestations. Although no clinical experience using dialysis as a treatment for Xeloda overdose has been reported, dialysis may be of benefit in reducing circulating concentrations of 5'-DFUR, a low-molecular-weight metabolite of the parent compound.
  
  Single doses of Capecitabine (Xeloda) were not lethal to mice, rats, and monkeys at doses up to 2000 mg/kg (2.4, 4.8, and 9.6 times the recommended human daily dose on a mg/m2 basis).
  
  
  Contraindications:
  
  
• Severe renal impairment.
• Hypersensitivity.
  
  
  Warnings and precautions:
  
  
• Coagulopathy: may result in bleeding, death. Monitor anticoagulant response (e.g., INR) and adjust anticoagulant dose accordingly.
• Diarrhea: may be severe. Interrupt Xeloda treatment immediately until diarrhea resolves or decreases to grade 1. Recommend standard antidiarrheal treatments.
• Cardiotoxicity: common in patients with a prior history of coronary artery disease.
• Increased risk of severe or fatal adverse reactions in patients with low or absent dihydropyrimidine dehydrogenase (DPD). Activity: withhold or permanently discontinue Capecitabine (Xeloda) tablets in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. No Xeloda dose has been proven safe in patients with absent DPD activity.
• Dehydration and renal failure: interrupt this medicine treatment until dehydration is corrected. Potential risk of acute renal failure secondary to dehydration. Monitor and correct dehydration.
• Embryo-fetal toxicity: can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.
• Mucocutaneous and dermatologic toxicity: severe mucocutaneous reactions, Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported. Xeloda should be permanently discontinued in patients who experience a severe mucocutaneous reaction during treatment. This drug may induce hand-and-foot syndrome. Persistent or severe hand-and-foot syndrome can lead to loss of fingerprints which could impact patient identification. Interrupt Capecitabine (Xeloda) treatment until the hand-and-foot syndrome event resolves or decreases in intensity.
• Hyperbilirubinemia: interrupt Xeloda treatment immediately until the hyperbilirubinemia resolves or decreases in intensity.
• Hematologic: do not treat patients with neutrophil counts < 1.5 x 109/L or thrombocyte counts < 100 x 109/L. If grade 3-4 neutropenia or thrombocytopenia occurs, stop therapy until condition resolves.
  
  
  Side effects, adverse reactions:
  
  Most common adverse reactions (>= 30%) were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia. Other adverse reactions, including serious adverse reactions, have been reported.
  
  To report suspected adverse reactions, contact Genentech, Inc pharmaceutical company or your local FDA.
  
  
  Drug interactions:
  
  
• Anticoagulants: monitor anticoagulant response (INR or prothrombin time) frequently in order to adjust the anticoagulant dose as needed.
• Phenytoin: monitor phenytoin levels in patients taking Xeloda pills concomitantly with phenytoin. The phenytoin dose may need to be reduced.
• Leucovorin: the concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
• CYP2C9 substrates: care should be exercised when Capecitabine (Xeloda) is coadministered with CYP2C9 substrates.
• Allopurinol: avoid the use of allopurinol during treatment with this medication.
• Food reduced both the rate and extent of absorption of capecitabine.
  
  Related medications:
  
  
• Progesterone 100 mg and 200 mg
• Sonata sleeping pill
  
  
  Use in specific populations:
  
  
• Lactation: advise women not to breastfeed.
• Females and males of reproductive potential: verify pregnancy status of females prior to initiation of Xeloda. Advise males with female partners of reproductive potential to use effective contraception.
• Geriatric: greater incidence of adverse reactions. Monitoring required.
• Hepatic impairment: monitoring is recommended in patients with mild to moderate hepatic impairment.
• Renal impairment: reduce capecitabine tablets starting dose in patients with moderate renal impairment.
  
  
  Where to buy capecitabine online:
  
  To purchase Xeloda (Capecitabine) 500 mg tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.
  
  
  Here is a list of popular medications containing dosulepin as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
  
  

  Trade name of the drug	Pharmaceutical forms and doses	Companies
  Capnat	Tablets, Film-Coated; Oral; Capecitabine 150 mg Tablets, Film-Coated; Oral; Capecitabine 500 mg	Pacific Pharmaceuticals
  Capegard	Tablets; Oral; Capecitabine 500 mg	Cipla
  Kapetral	Tablets, Film-Coated; Oral; Capecitabine 150 mg Tablets, Film-Coated; Oral; Capecitabine 500 mg	Remedica
  Naprocap	Tablets, Film-Coated; Oral; Capecitabine 500 mg	Pacific Pharmaceuticals
  Xeloda	Tablets, Film-Coated; Oral; Capecitabine 150 mg Tablets, Film-Coated; Oral; Capecitabine 500 mg	Genentech Roche